Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer

Published:2019-06 Issue: Volume:132 Page:65-71
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Assoun Sandra,Theou-Anton Nathalie,Nguenang Marina,Cazes Aurélie,Danel Claire,Abbar Baptiste,Pluvy Johan,Gounant Valérie,Khalil Antoine,Namour Céline,Brosseau Solenn,Zalcman Gérard^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference37 articles.

1. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N. Engl. J. Med.,2015

2. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N. Engl. J. Med.,2015

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med.,2016

4. PD-1 blockade in tumors with mismatch-repair deficiency;Le;N. Engl. J. Med.,2015

5. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade;Le;Science.,2017

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census;npj Precision Oncology;2024-08-09

2. Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis;Swiss Medical Weekly;2024-07-25

3. p53 at the crossroads of tumor immunity;Nature Cancer;2024-07-15

4. The role of immunotherapy in early-stage and metastatic NSCLC;Pathology and Oncology Research;2024-07-04

5. Insights into treatment-specific prognostic somatic mutations in NSCLC from the AACR NSCLC GENIE BPC cohort analysis;BMC Pulmonary Medicine;2024-07-02